EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

•EGFR exon 20 insertion mutations occur in ~2–3% of all NSCLC cases.•Activity of 1st to 3rd generation EGFR-TKI is less in EGFR ex20ins versus common mutations.•Osimertinib might play a role in the treatment of EGFR ex20ins mutations.•Poziotinib, mobocertinib and amivantamab are promising new EGFR e...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer treatment reviews Ročník 90; s. 102105
Hlavní autoři:	Remon, Jordi, Hendriks, Lizza E.L., Cardona, Andres F., Besse, Benjamin
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier Ltd 01.11.2020
Témata:	Amivantamab Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic EGFR exon 20 insertions ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Exons Genes, erbB-1 Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Osimertinib Poziotinib Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Randomized Controlled Trials as Topic TAK-788 Osimertinib Poziotinib TAK-788 EGFR exon 20 insertions Amivantamab
ISSN:	0305-7372, 1532-1967, 1532-1967
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!